Innate Pharma to get $5M from AstraZeneca as IPH5201 heads to phase 2 study in lung cancer
Fotonen/iStock Editorial via Getty Images         

France's Innate Pharma (NASDAQ:IPHA)Â said it will receiveÂ a $5M milestone payment from AstraZeneca (NASDAQ:AZN) as its monoclonal antibody IPH5201Â will advance into a phase 2 trial in lung cancer.
Innate will be responsible for conducting the study, while the two companies will share study costs and the British pharma giant will supply clinical trial drugs.
Innate noted thatÂ AstraZeneca conducted a phase 1 trial in solid tumors with IPH5201 alone or in combination with durvalumab. The data is expected to be presented at an upcoming medical meeting.